Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Post by Ingiboyon Aug 09, 2023 1:08pm
95 Views
Post# 35579853

Arbitration Time and Cost

Arbitration Time and CostMore from the Aceris Law article:

"A common trend, recognized by most arbitral institutions, is that there is generally a need to reduce both the time and cost of international arbitration, which is why institutions are working on implementing various techniques for controlling time and cost in arbitration and updating their procedural rules accordingly.

It should finally also be noted that, while the time and costs of arbitration are often interrelated, as costs typically depend on the time spent by tribunals and legal counsel on the case, this is not always the case. Different arbitral institutions have different methodologies for calculating their administrative fees and the fees of arbitral tribunals (see The Costs of Arbitration). In addition, certain arbitration law firms offer capped fee arrangements to their clients for the entire arbitration, instead of billing their clients on an hourly basis, which can not only lead to a significant cost reduction but also demonstrates that the time and cost of arbitration are not always linked."

This certainly not the case with this Arbitration.  As noted before, this Arbitration will have been in session for 22 months at the end of August which is well beyond the average and mean duration.

One could read many scenarios into this:
Size of the compensation (award) requested
Complexity of the Case
Both parties may be working on a compromised deal

 


<< Previous
Bullboard Posts
Next >>